Evidence map›Paper›PMID 28571635›Full record

ArticleJournal of the American College of Cardiology2017

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.

Tatendashe B Dondo, Marlous Hall, Robert M West, Tomas Jernberg, Bertil Lindahl, Hector Bueno, Nicolas Danchin, John E Deanfield, Harry Hemingway, Keith A A Fox and 2 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 7 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02786654 completednot on this map

β Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure

Typeobservational_patient_registrySponsorUniversity of LeedsRan2007 to 2013Enrolled179,810ConditionsAcute Myocardial Infarction
NCT04788186 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

BEta Blocker dEprescription Following Coronary Artery Bypass Graft sURGERy: Feasibility and Safety Pilot (BEEFBURGER Trial)

TypeinterventionalSponsorUniversity of SaskatchewanRan2021 to 2025Enrolled200ConditionsCoronary Artery Disease, Acute Myocardial Infarction, Coronary Artery Stenosis, ST Elevation Myocardial InfarctionArmsDe-prescribe beta blocker therapy
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 7 syntheses or guidelines pooled it, 220 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 4 countries.

Tatendashe B DondoMedical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.
Marlous HallMedical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.
Robert M WestLeeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom.
Tomas JernbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Bertil LindahlUppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Hector BuenoCentro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Instituto de Investigación i+12 and Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
Nicolas DanchinDepartment of Cardiology, Hôpital Européen Georges Pompidou, Paris, France; Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris-Descartes, Paris, France.
John E DeanfieldNational Institute for Cardiovascular Outcomes Research, University College London, London, United Kingdom.
Harry HemingwayUniversity College London, London, and Farr Institute of Health Informatics Research, London, United Kingdom.
Keith A A FoxCentre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
Adam D TimmisThe National Institute for Health Biomedical Research Unit, Bart's Heart Centre, London, United Kingdom.
Chris P GaleMedical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom; Department of Cardiology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom. Electronic address: c.p.gale@leeds.ac.uk.
University of Leeds · GBNational Institute for Health Research · GBFarr Institute · GBKarolinska Institutet · SEMedical Research Council · GBUniversidad Complutense de Madrid · ESUniversité Paris Cité · FRUniversity of Edinburgh · GBUppsala University · SE

Funding

Medical Research Council MC_PC_13041Medical Research Council MR/K006584/1Wellcome Trust 206470/Z/17/Z
6 · The paper itself

Abstract

backgroundFor acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality.

objectivesThe goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD).

methodsThis cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality.

resultsOf 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819).

conclusionsAmong survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).

Indexed as

RegistriesAdrenergic beta-AntagonistsAgedDose-Response Relationship, DrugElectrocardiographyFemaleFollow-Up StudiesHeart FailureHospital MortalityHumansMaleMiddle AgedMyocardial InfarctionPropensity ScoreProspective StudiesSurvival RateAdrenergic beta-Antagonistsaverage treatment effectNSTEMIpreserved left ventricular systolic functionpropensity scoreSTEMIsurvival

Identifiers

PMID28571635
PMCPMC5457288
OpenAlexW2617274206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.